Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Santen’s Glaucoma Drug Tapcom Launched in China
September 2, 2025
- Takeda Wins Japan Approval for Takhzyro Pen Formulation
September 2, 2025
- Specialist Highlights Lfynua’s Potential for Refractory Chronic Cough
September 1, 2025
- Medipal, JCR Expand Tie-Up to GM2 Gangliosidosis Drug JR-479
September 1, 2025
- NEC Touts AI as Core of Personalized Cancer Vaccine Development
September 1, 2025
- Meiji Bags Japan Approval for 2-Dose COVID Vaccine Vial
September 1, 2025
- Mitsubishi Tanabe Taps Ex-Pfizer Japan Chief as CEO, Ex-Takeda CFO as Chairman
August 29, 2025
- Resilire Seeks to Double Pharma Clients for Supply Chain Visualization Platform
August 29, 2025
- Novo Hooks Up with Hirosaki City on Obesity Program for Young Adults
August 29, 2025
- New PIII Breast Cancer Trial Kicks Off for Daiichi’s HER3 ADC
August 29, 2025
- Sanofi Files for Subcutaneous Formulation of Sarclisa in Japan
August 29, 2025
- BeOne’s Tevimbra Could Stand Apart in PD-1 Class with Unique Feature: Expert
August 28, 2025
- Sawai to Raise Awareness for Launch of Alcoholism Therapy App HAUDY
August 28, 2025
- Meiji Breaks Ground on “Dual-Use” Plant for Antibiotics and Vaccines
August 28, 2025
- Nihon Chouzai Shuts Down FINDAT Formulary Biz amid Tepid Demand
August 28, 2025
- Amicus’ Pompe Disease Drugs Hit Japan Market
August 28, 2025
- LP.8.1-Tailored Nuvaxovid COVID Jab Approved in Japan: Takeda
August 28, 2025
- Kringle, Keio Pair Up on HGF Therapy for Peripheral Nerve Injury
August 27, 2025
- ASKA Presses Dalton for Transparency on 30% Stake Plan
August 26, 2025
- Meiji Revives Penicillin Raw Material Production in Japan after 31 Years, Races to Pass Down Know-How
August 26, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…